ISSN: 2155-9899
Journal of Clinical & Cellular Immunology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Immune Response and Apoptosis ? Introduction

Charles J. Malemud1*, Azizul Haque2, Nancy A. Louis3 and Jin Wang4
1Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106
2Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29425
3Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Emory University School of Medicine, Atlanta, Georgia 30322
4Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas 77030
Corresponding Author : Charles J. Malemud
Department of Medicine, Division of Rheumatic Diseases
University Hospitals Case Medical Center
2061 Cornell Road, Room 207, Cleveland, Ohio 44106-5076, USA
Tel: (216) 844-7846
Fax: (216) 844-2288
E-mail: cjm4@cwru.edu
Received January 04, 2012; Accepted January 05, 2012; Published January 06, 2012
Citation: Malemud CJ, Haque A, Louis NA, Wang J (2012) Immune Response and Apoptosis – Introduction. J Clin Cell Immunol S3:e001. doi:10.4172/2155-9899.S3-e001
Copyright: © 2012 Malemud CJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Clinical & Cellular Immunology

Programmed cell death or apoptosis is one of the major contributors to the development of a normal immune system, the developmentally correct architecture of tissues and organs and the proper maintenance of organ homeostasis. However, dysfunctional induction of apoptosis appears to be critical for the aberrant survival of pathological cells in many chronic immune-mediated disorders, inflammation and cancer.
This Special Issue of the Journal of Clinical and Cellular Immunology devoted to “Immune Response and Apoptosis” reviews the recent advances in our understanding of how the balance between cell survival and apoptosis is regulated and maintained in the normal state including the role apoptosis plays in regulating T-lymphocyte development, how apoptosis acts as a fundamental cellular process responsible for suppressing the activity of antigen-presenting dendritic cells (DCs) a key step in controlling immune tolerance, and how apoptosis acts as the critical modulator of innate and adaptive immunity.
Several pathologies are also reviewed. These disorders are characterized either by an abnormally low frequency of apoptosis with a skewed number of pathological cells surviving and outnumbering those deleted by apoptosis or by the aberrant deletion and lost vitality of normal cells. Thus, aberrant apoptosis is intimately associated with both the pathogenesis and progression of chronic inflammatory diseases such as intestinal bowel disease (IBD), rheumatoid arthritis (RA) and necrotizing enterocolitis (NEC). Finally, from a therapeutic perspective, ganoderic acids are proposed as drugs which modulate cancer cell proliferation and immune cell activation via their capacity to induce apoptosis. This focus demonstrates the chemotherapeutic potential of natural products in influencing research in this area.
Apoptosis Regulates Normal Immune Cell Development
Carolina Francelin and Liana Verinaud (Institute of Biology, State University of Campinas, São Paulo, BRAZIL) review the evidence that apoptosis regulates T-lymphocyte (i.e. T-cells) development through positive and negative selection [1-3]. Of note, the results of several studies [4-6] have shown that T-cell receptor (TCR)-independent, ligand-induced TCR-signaling and the relative expression of pro- and anti-apoptotic proteins during intrathymic development lead either to rescue from cell death through positive T-cell selection and/or cell death via negative T-cell selection.
DCs are considered the most efficient antigen-presenting cells in both lymphoid and non-lymphoid tissues [7]. Min Chen and Jin Wang (Baylor College of Medicine, Houston, Texas, USA) review the accumulated evidence showing that dysregulated DC apoptosis results in abnormal DC survival which is associated with the development of systemic autoimmune diseases [8,9]. Thus, maintenance of the correct number and activity of DCs is required for maintaining immune system homeostasis, including the capacity to orchestrate appropriate inflammatory responses and the regulation of immune tolerance.
A detailed review of apoptosis as the ultimate immunomodulatory cellular event is presented by Anuradha K. Murali and Shikhar Mehrotra (Medical University of South Carolina, Charleston, South Carolina, USA). These investigators point out that impairment of apoptotic pathways or the lack of strict regulation of apoptosis results in autoimmune and inflammatory disorders, viral and bacterial infections as well as cancer. Importantly, recent evidence implicating specific microRNAs in regulating a special form of T-cell death called rapid-activation-induced cell death [10] is discussed.
Role of Impaired Apoptosis in IBD, RA and NEC
IBD is a term used to describe two mutually independent yet chronic inflammatory conditions of the intestine namely, ulcerative colitis and Crohn’s disease. Importantly, key mediators of apoptosis and autophagy are implicated in the genetic susceptibility, pathogenesis and perpetuation of IBD [11-13]. Michael Schnoor (Max-Planck-Institute of Molecular Biomedicine, Münster, GERMANY) and Nancy A. Louis (Emory University School of Medicine, Atlanta, Georgia, USA) review how pro-inflammatory cytokines skew the balance between pro- and anti-apoptotic responses of the intestinal epithelium that primarily result from activation of key pathways involving type I [14] and type II interferon proteins [15], nuclear factor-κB (NF-κB) [16], and Wntmediated signaling [17,18], as well as the role that oxygen tension [19] and nutritional factors [20] play in regulating these pathways.
In RA, elevated levels of the pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-(IL)-1β, IL-6, IL-17 and interferon-γ, among others, results in a skewing of the balance between the survival of cells in synovial tissue and apoptosis, favoring the former. Charles J. Malemud (Case Western Reserve University School of Medicine, Cleveland, Ohio, USA) reviews the cellular mechanisms in RA that favor synoviocyte, immune and inflammatory cell activation, proliferation and survival with resultant synovial tissue hyperplasia and chronic inflammation characterized by resistance to apoptosis. This resistance to apoptosis has been connected to a deregulated activation of the Stress-Activated Protein Kinase/Mitogen-Activated Protein Kinase (SAPK/MAPK) and the Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathways by these cytokines and also by “cross-talk” between activated SAPK/MAPK and JAK/STAT pathways and the PI3/Akt/PTEN/mTOR pathway, the latter favoring the survival of activated synoviocytes, immune and inflammatory cells in RA synovium [21-26]. Furthermore, the mechanism(s) of action whereby disease-modifying anti-rheumatic drugs (e.g. methotrexate) and/or disease modifying anti-rheumatic biologic drugs (e.g. TNF-α antagonists, IL-1 receptor antagonist, IL-6 receptor antagonist) suppress the clinical activity of RA is also discussed focusing on how these therapeutic interventions may also play a crucial role in restoring the balance between cell survival and apoptosis in RA synovial tissue [27-29].
Tamas Jilling, Jing Lu and Michael Caplan (NorthShore University Health System Research Institute and University of Chicago Pritzker School of Medicine, Evanston, Illinois, USA) review the evidence demonstrating the role that deregulated enterocyte apoptosis plays in the pathogenesis of NEC. They point out the potentially critical role played by several inflammatory mediators including platelet-activating factor, TNF-α, Toll-like receptors and IL-8 [30-33] in activating signal transduction pathways that cause mucosal injury as reflected by the activation of mitochondrial-derived pro-caspase(s) and NF-κB activation.
Chemotherapy with Ganoderic Acid Induces Apoptosis
The anti-tumor properties of the Ganoderma lucidum mushroom are reviewed by Faisal F.Y. Radwan, J. Manuel Perez and Azizul Haque (Medical University of South Carolina, Charleston, South Carolina, USA). The ganoderic acids are methanol-soluble triterpenoids [34] derived from Ganoderma lucidum with potent cancer chemotherapeutic activity [35]. Although significant compelling evidence reveals that ganoderic acids induce apoptosis in cancer cells [36-38] with a lower toxicity towards normal cells, more recently published data showed that ganoderic acids can also alter the immune system and its antitumor activity [39,40]. The long-term goal of employing nanoparticle polymer-coated [41] ganoderic acid for the targeted delivery of these Ganoderma lucidum-derived compounds to malignant tissues in vivo is also discussed.
Taken together, these reviews underscore the critical nature of the tight regulation of apoptosis in development, inflammation, and cancer. It is clear that apoptotic pathways provide promising targets for the prevention or attenuation of disease in multiple tissues. However, the complex balance of pro- and anti-apoptotic proteins regulating cellular function and tissue homeostasis must be considered during the rationale design of cell and tissue-specific tools to manipulate these processes.
Disclosure Statement
The authors disclose no conflict of interest.
References









































Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11415
  • [From(publication date):
    April-2012 - Jul 25, 2016]
  • Breakdown by view type
  • HTML page views : 7678
  • PDF downloads :3737
 
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version